The developers of Schedule I face copyright infringement allegations, but backlash has shifted toward their accuser as fans review-bomb the plaintiff's games. Explore the details of this copyright claim and what's coming in Schedule I's next update.
Latest Developments in Schedule I
Steam Users Bombard Accuser's Games With Negative Reviews
Movie Games S.A., creators of The Drug Dealer Simulator series, have accused indie title Schedule I of copyright violations. A legal analysis published by the Polish Press Agency on April 3 suggests potential infringement of IP rights, including similarities in narrative, gameplay mechanics, and interface design.
While official proceedings remain pending, fan sentiment overwhelmingly favors Schedule I. The accuser's games—The Drug Dealer Simulator and its sequel—now bear Steam's "Overwhelmingly Negative" and "Mostly Negative" review statuses respectively following coordinated negative feedback.
Reviewers primarily criticize Movie Games S.A. for targeting an indie developer while ignoring similar titles in the genre, despite their series' reputation as standout crime management games. This community backlash occurs as Schedule I enjoys unprecedented success.
The cooperative crime simulator, which launched in Early Access on March 25, tasks players with building a drug empire from humble beginnings. Currently ranking as Steam's #2 top-seller with "Overwhelmingly Positive" reviews, it boasts 459,075 peak concurrent players—surpassing major titles like inZOI and Monster Hunter Wilds.
Our Game8 team found Schedule I delivers an unexpectedly compelling experience, essentially functioning as a "Breaking Bad" simulator. For our full analysis of the Early Access release, read our featured coverage.
